Kwality raises FY27 revenue guidance to Rs 720 crore-plus

Kwality Pharmaceuticals Ltd raised its FY27 revenue guidance to Rs 720 crore-plus from Rs 700 crore after Q2FY27 revenue from operations rose 62% year on year to Rs 181.2 crore, while earnings before interest, tax, depreciation and amortisation (EBITDA) margin reached 27.5%.

What did Kwality report in Q2FY27?

Kwality reported revenue from operations of Rs 181.2 crore in Q2FY27, up 62% from Rs 111 crore in Q2FY26 and 12% from Rs 162.4 crore in Q1FY27. Gross profit rose 67% year on year to Rs 94.5 crore from Rs 56.5 crore, while the quarter-on-quarter increase in gross profit was 26% from Rs 75 crore.

The company reported EBITDA of Rs 49.8 crore, 96% above Rs 25.4 crore in Q2FY26 and 21% above Rs 41.1 crore in Q1FY27. Profit after tax (PAT) was Rs 29 crore, compared with Rs 14.1 crore a year earlier and Rs 25.6 crore in the preceding quarter, representing year-on-year growth of 106% and sequential growth of 13%.

Why did Kwality raise its FY27 revenue guidance?

Kwality’s presentation does not state a single quantified reason for the revision, but its guidance tracker raises the FY27 revenue target to Rs 720 crore-plus from Rs 700 crore earlier. The revised target implies growth of 43% or more over FY26 actual revenue of Rs 503 crore, according to the company’s stated calculation.

Management retained its FY27 EBITDA guidance of Rs 189 crore to Rs 196 crore-plus, with a margin of 27% to 28%-plus. It raised the PAT target to Rs 122 crore-plus, with an approximately 17%-plus margin, from the earlier target of Rs 109 crore and an approximately 15.5%-plus margin.

Q1FY27 and Q2FY27 revenue totalled Rs 343.6 crore, based on reported quarterly revenue of Rs 162.4 crore and Rs 181.2 crore, respectively. To exceed the revised Rs 720 crore threshold, Kwality would need to record more than Rs 376.4 crore during H2FY27; the presentation does not provide quarterly revenue guidance for that period.

How did Kwality's Q2FY27 profitability change?

Kwality’s Q2FY27 EBITDA margin was 27.5%, compared with 23.4% in Q2FY26 and 25.3% in Q1FY27. Its PAT margin was 16%, up from 13% a year earlier and unchanged from the 16% reported for Q1FY27 in the quarterly performance summary.

Cost of goods sold was Rs 86.7 crore in Q2FY27, 59% above Rs 54.5 crore in Q2FY26 but 1% below Rs 87.4 crore in Q1FY27. Revenue increased 62% year on year and 12% quarter on quarter, while gross profit increased 67% year on year and 26% sequentially to Rs 94.5 crore.

Employee benefits expense rose 41% year on year to Rs 18.8 crore, and other expenses increased 46% to Rs 25.9 crore. Finance cost was Rs 3 crore, up 7% from Rs 2.8 crore, and depreciation and amortisation expense rose 10% to Rs 5.4 crore; profit before tax consequently reached Rs 42.2 crore, up 128% year on year.

What operational milestones support Kwality's outlook?

Kwality reported new registrations across Latin America, including Mexico and Colombia, the Middle East and North Africa, the Gulf Cooperation Council, and selected Asian markets including Malaysia. The company identified its registered-business model as the mechanism for market-by-market expansion, although the presentation does not disclose revenue by geography or registrations secured during Q2FY27.

The company received European Union Good Manufacturing Practice certification from Hungary for its Cephalosporin and Oncology plants, as well as its General and Beta Lactam plants. Kwality said these certifications enable expanded access to European Union-regulated markets, while an Eurasian audit of the General Plant was completed to support entry into Eurasian countries.

Kwality continued bioequivalence programmes covering more than 40 oral solid-dosage products and six injectables across multiple therapies, completing 11 bioequivalence studies during Q2FY27. Its research pipeline also includes three generics of currently patented molecules, with proof of concept achieved for one product.

Which capacity and regulatory actions remain underway?

Kwality said biologics and oncology capacity expansion remains underway, with the oncology expansion planned by June 2027. Construction of its new hormone manufacturing facility has been completed, and a manufacturing-licence audit has been triggered, leaving that regulatory process as a disclosed step before the facility can progress further.

In development programmes, erythropoietin pre-clinical outcomes have advanced to the clinical-trial stage, and Kwality has received permission to take a pre-clinical batch for Pembrolizumab. An audit was also conducted for the ophthalmic line, and the company is proceeding towards a Medical Device Regulation audit for that line.

Conclusion

Kwality’s revised Rs 720 crore-plus FY27 revenue target follows a Q2FY27 in which revenue reached Rs 181.2 crore, gross profit was Rs 94.5 crore and EBITDA was Rs 49.8 crore. Compared with Q2FY26, revenue increased 62%, EBITDA increased 96%, and the EBITDA margin rose by 4.1 percentage points to 27.5%.

The next reported measure is H2FY27 execution against the revised revenue threshold, after Rs 343.6 crore of revenue in the first two quarters. Management’s disclosed milestones to watch include the hormone-facility manufacturing-licence audit, the ophthalmic-line Medical Device Regulation audit, and the planned oncology-capacity expansion by June 2027.